Coverage: The Meridian legal market record (editorial).
South Africa is expressly a licensed territory and the licensee operates a leading South African pharmaceutical business.
| Record ID | TX-AFR-2026-0008 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Exclusive licence, In-licensing |
| IP rights | patent, regulatory data, not specified by source |
| Status | Signed |
| Qualifying date | 2026-08-29 |
| Sector | Life sciences · Pharmaceuticals – oncology |
| African markets | South Africa |
| Licensed territory | Seven markets: India, South Africa and five other emerging markets that the release does not name. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 2 source(s) |
| Last verified | 2026-10-25 |
Parties
- Cipla (India): licensee
- SBP Group (China): licensor
- CTTQ (China): licensor, manufacturer
Key terms
- Interest: exclusive licence to develop and commercialise; Exclusivity: exclusive; Territorial scope: India, South Africa and five other emerging markets; Field of use: HER2-expressing cancers, including breast cancer
Sources
- Cipla and SBP Group sign exclusive licensing agreement for Rolditamig Deuderuxtecan (TQB2102), Cipla Limited, 2026-08-29
- Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets, CNBC TV18, 2026-08-31
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


